Literature DB >> 4027482

The effects of dopexamine on the cardiovascular system of the dog.

R A Brown, J B Farmer, J C Hall, R G Humphries, S E O'Connor, G W Smith.   

Abstract

The cardiovascular effects of dopexamine and dopamine were compared in the anaesthetized and conscious dog by the use of intravenous infusions over the dose range 3 X 10(-9) - 10(-7)mol kg-1 min-1. In the anaesthetized dog, dopexamine produced a dose-related fall in blood pressure due to peripheral vasodilatation and a small rise in heart rate and contractility. By contrast, dopamine did not significantly reduce blood pressure but produced a larger dose-related increase in contractility. At the highest infusion rate (10(-7)mol kg-1 min-1) blood pressure and heart rate were increased by dopamine. Dopexamine dilated the renal and mesenteric vascular beds with a potency similar to that of dopamine. Femoral vascular responses produced by both agents were inconsistent but the highest infusion rate of dopamine did produce vasoconstriction. With the aid of selective receptor antagonists (haloperidol, propranolol and bulbocapnine) the vasodepressor activity of dopexamine was shown to be mediated by stimulation of DA2-, beta- and DA1-receptors. The cardiac stimulation and renal vasodilatation produced by both compounds were due to stimulation of beta-adrenoceptors and DA1-receptors respectively. In the conscious dog, intravenous infusion of dopexamine caused a dose-related fall in blood pressure, renal vasodilatation and an increase in cardiac contractility and heart rate. Dopamine also increased cardiac contractility, and renal blood flow due to renal vasodilatation but without affecting heart rate. At the highest infusion rate, blood pressure was increased. Dopexamine and dopamine produced a similar incidence of panting and repetitive licking at 3 X 10(-8)mol kg-1 min-1 and emesis at 10(-7)mol kg-1 min-1, due to stimulation of dopamine receptors in the chemoreceptor trigger zone. Dopexamine produces a different cardiovascular profile from dopamine in the anaesthetized and conscious dog. Both compounds reduce renal vascular resistance, but in contrast to dopamine, dopexamine reduces afterload and produces only mild inotropic stimulation. These differences reflect contrasting activity at adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027482      PMCID: PMC1916515          DOI: 10.1111/j.1476-5381.1985.tb10555.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  Vasodilator therapy of cardiac failure (second of two parts).

Authors:  J N Cohn; J A Franciosa
Journal:  N Engl J Med       Date:  1977-08-04       Impact factor: 91.245

2.  Heart rate lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of central dopamine receptors leading to inhibition of sympathetic tone and enhancement of parasympathetic outflow.

Authors:  I Cavero; F Lefèvre-Borg; R Gomeni
Journal:  J Pharmacol Exp Ther       Date:  1981-11       Impact factor: 4.030

Review 3.  Vasodilator therapy for chronic heart failure.

Authors:  K Chatterjee; W W Parmley
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

4.  Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle.

Authors:  B Sharma; J F Goodwin
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

5.  Hemodynamic consequences of administration of phentolamine or nitroprusside with dopamine in the dog.

Authors:  Y Y Hsieh; L I Goldberg
Journal:  J Cardiovasc Pharmacol       Date:  1979 May-Jun       Impact factor: 3.105

6.  Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.

Authors:  I Cavero; F Lefèvre-Borg; R Gomeni
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

7.  Comparison of haemodynamic responses to dobutamine and salbutamol in cardiogenic shock after acute myocardial infarction.

Authors:  M B Fowler; A D Timmis; J P Crick; R Vincent; D A Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

8.  Detection of dopamine receptors in the area postrema.

Authors:  E Stafanini; Y Clement-Cormier
Journal:  Eur J Pharmacol       Date:  1981-09-11       Impact factor: 4.432

9.  Hypotensive effects of N,N-din-n-propylodopamine in the anesthetized dog: comparison with sodium nitroprusside.

Authors:  W H Fennell; J D Kohli; L I Goldberg
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

10.  Comparison of haemodynamic responses to dopamine and salbutamol in severe cardiogenic shock complicating acute myocardial infarction.

Authors:  A D Timmis; M B Fowler; D A Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-03
View more
  21 in total

Review 1.  New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Authors:  P T Horn; M B Murphy
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure.

Authors:  J J Murphy; J R Hampton
Journal:  Br Heart J       Date:  1988-07

3.  Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility?

Authors:  O E Brodde; H R Zerkowski
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

4.  Inhibition of 3H-noradrenaline accumulation by dopexamine hydrochloride in the isolated aorta of the rabbit.

Authors:  O A Nedergaard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

Review 5.  Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Authors:  T Meinertz; H Drexler; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 6.  Intensive care medicine--a review.

Authors:  J Wendon; J Coltart
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

7.  Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: a study in normal healthy volunteers.

Authors:  S Mousdale; P A Clyburn; A M Mackie; N D Groves; M Rosen
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

8.  Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.

Authors:  R A Brown; J Dixon; J B Farmer; J C Hall; R G Humphries; F Ince; S E O'Connor; W T Simpson; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

9.  Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study.

Authors:  H Asanoi; S Sasayama; T Sakurai; J D Lee; M Kinoshita; T Ishimura; J Yoshikawa; K Mitsudo; H Sato; S Morioka
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

10.  Dopexamine maintains mesenteric blood flow during systemic hypoxemia in the neonatal piglet.

Authors:  T V Thomas; T P Mace; E U Choe; L M Flint; J J Ferrara
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.